Study guide
16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
Key Takeaways Explain This Topic AI
Paroxetine mesylate 7.5 mg is the only non-hormonal agent FDA-approved for vasomotor symptoms among the SSRIs.
Paroxetine is contraindicated with tamoxifen because potent CYP2D6 inhibition blocks conversion to the active metabolite, and venlafaxine is preferred instead.
Neurokinin-3 receptor antagonists such as fezolinetant act on the hypothalamic thermoregulatory center and require liver function monitoring.
Osteoporosis is a T-score of minus 2.5 or lower, and osteopenia is between minus 1.0 and minus 2.5.
Oral bisphosphonates are first-line antiresorptive therapy and must be taken on arising with a full glass of plain water, 30 to 60 minutes before anything else, remaining upright for at least 30 minutes.
Last updated: September 2026
Non-Hormonal Pharmacologic Therapies for Vasomotor Symptoms
For individuals with absolute contraindications to estrogen (e.g., breast cancer survivors, thromboembolic history) or those who decline hormones, several evidence-based non-hormonal alternatives exist: Non-Hormonal Therapies for Vasomotor Symptoms (VMS)
- ├── First-in-Class Targeted Mechanism: Neurokinin 3 (NK3) Receptor Antagonist
- │ └── Fezolinetant (Veozah 45 mg PO daily) ──> Directly blocks NKB on KNDy neurons
│ └── Non-hormonal, non-sedating; MANDATORY baseline & periodic LFT monitoring!
- ├── Serotonergic / Noradrenergic Neuromodulators
- │ ├── Paroxetine mesylate (7.5 mg PO qhs) ──> Only FDA-approved SSRI for VMS
- │ │ └── CONTRAINDICATED with Tamoxifen! (Potent CYP2D6 inhibitor blocks tamoxifen activation)
- │ ├── Venlafaxine (37.5–75 mg PO daily - SNRI) ──> Preferred first-line for patients on Tamoxifen
- │ └── Escitalopram (10–20 mg PO daily - SSRI)
- └── Centrally Acting Neuroactive Agents
- ├── Gabapentin (300–900 mg PO at bedtime) ──> Excellent for nocturnal hot flashes & insomnia
- └── Clonidine (0.05–0.1 mg PO daily or transdermal patch - Alpha-2 adrenergic agonist)
Fezolinetant (Veozah): A breakthrough, FDA-approved, non-hormonal Neurokinin 3 (NK3) receptor antagonist (45 mg PO once daily). By directly blocking neurokinin B binding on hypertrophied KNDy neurons in the hypothalamic thermoregulatory center, it restores normal set-point firing without any estrogenic activity.
Clinical Safety Imperative: Requires baseline liver function tests (ALT, AST, total bilirubin) prior to initiation, followed by routine monitoring at 3, 6, and 9 months. Contraindicated in severe renal impairment (eGFR <30 mL/min) or cirrhosis.
SSRIs and SNRIs: Modulate central serotonin and norepinephrine levels, stabilizing the hypothalamic thermoregulatory center and reducing hot flash frequency by 50% to 65%.
Paroxetine: Paroxetine mesylate 7.5 mg daily is FDA-approved for VMS.
Tamoxifen Interaction Warning: Paroxetine and fluoxetine are potent CYP2D6 enzyme inhibitors that block the bioactivation of tamoxifen into its active therapeutic metabolite ( endoxifen ). Therefore, paroxetine and fluoxetine are strictly contraindicated in breast cancer patients taking tamoxifen . In these patients, Venlafaxine (an SNRI with minimal CYP2D6 inhibition) is the first-line non-hormonal agent of choice.
Gabapentin: An anticonvulsant and neuropathic pain agent (300 to 900 mg taken orally at bedtime). Provides substantial reductions in hot flash severity and night sweats, making it particularly beneficial for women whose primary complaint is nocturnal awakenings and insomnia.
Postmenopausal Osteoporosis Prevention & Management
Postmenopausal osteoporosis is a skeletal disease characterized by low bone mass, microarchitectural deterioration of bone tissue, and compromised bone strength, leading to fragility fractures (vertebral compression, hip, and distal radius / Colles fractures).
Screening & Diagnostic Criteria (DEXA & T-Scores)
Universal Screening: Bone Mineral Density (BMD) testing via Dual-Energy X-ray Absorptiometry (DEXA) is universally recommended for:
All postmenopausal women aged ≥65 years , regardless of clinical risk factors.
Postmenopausal women <65 years with clinical risk factors for fracture (e.g., low body weight <127 lbs, parental history of hip fracture, current smoking, chronic oral glucocorticoid therapy, rheumatoid arthritis, excessive alcohol intake), or whose 10-year major osteoporotic fracture risk on the FRAX tool meets the threshold equivalent to a 65-year-old woman with no additional risk factors (commonly cited as 8.4% ; published estimates range from about 8.4% to 9.3% depending on the reference cohort).
World Health Organization (WHO) T-Score Diagnostic Criteria:
Normal: T-score ≥ -1.0 SD (within 1 SD of a young adult reference mean).
Osteopenia (Low Bone Mass): T-score between -1.0 and -2.5 SD .
Osteoporosis: T-score ≤ -2.5 SD at the femoral neck, total hip, or lumbar spine; OR the occurrence of an adult fragility fracture (fall from standing height or less), regardless of T-score.
Non-Pharmacologic Foundation
Calcium & Vitamin D: Total elemental calcium intake of 1,200 mg/day (optimally achieved through dietary sources; add calcium carbonate or calcium citrate supplements if diet is deficient). Vitamin D3 supplementation of 800 to 1,000 IU/day to maintain serum 25-hydroxyvitamin D levels ≥30 ng/mL.
Lifestyle: Regular weight-bearing exercise (walking, jogging, dancing) and resistance/muscle-strengthening training; smoking cessation; limiting alcohol to <2 drinks/day; home fall-prevention assessments.
Pharmacologic Antiresorptive Therapy
Oral Bisphosphonates (Alendronate 70 mg PO once weekly, Risedronate 35 mg weekly): First-line antiresorptive pharmacotherapy for diagnosed osteoporosis or high fracture risk (T-score ≤ -2.5 or FRAX 10-year hip fracture risk ≥3%). Bisphosphonates incorporate into the bone hydroxyapatite matrix and inhibit osteoclast farnesyl pyrophosphate synthase, inducing osteoclast apoptosis and halting bone resorption.
Strict Oral Administration Instructions (Prevention of Chemical Pill Esophagitis):
Take first thing in the morning upon arising with a full 8-ounce glass of plain water only (never juice, coffee, or mineral water).
Take on an empty stomach at least 30 to 60 minutes before any food, beverage, or other medications (oral bioavailability is <1%).
Must remain completely upright (sitting or standing) for at least 30 minutes (60 minutes for ibandronate) after swallowing the tablet; do NOT recline or lie down to prevent pill retention in the esophagus and severe chemical ulcerative esophagitis.
Rare Long-Term Complications: Medication-related osteonecrosis of the jaw (ONJ) and atypical subtrochanteric femur fractures. Bisphosphonate "drug holidays" (temporary discontinuation after 3 to 5 years of stability in moderate-risk patients) are frequently considered to mitigate these risks.